EP1966113A1 - Method for producing an alpha-chiral chloromethyl compound in a pure form - Google Patents
Method for producing an alpha-chiral chloromethyl compound in a pure formInfo
- Publication number
- EP1966113A1 EP1966113A1 EP06841346A EP06841346A EP1966113A1 EP 1966113 A1 EP1966113 A1 EP 1966113A1 EP 06841346 A EP06841346 A EP 06841346A EP 06841346 A EP06841346 A EP 06841346A EP 1966113 A1 EP1966113 A1 EP 1966113A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- compound
- mixtures
- preparation
- optically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 chloromethyl compound Chemical class 0.000 title abstract description 6
- 238000004519 manufacturing process Methods 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 84
- 238000009835 boiling Methods 0.000 claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 239000012535 impurity Substances 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims description 37
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 35
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 15
- 238000007700 distillative separation Methods 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 239000006227 byproduct Substances 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 239000010409 thin film Substances 0.000 claims description 4
- 238000001944 continuous distillation Methods 0.000 claims description 3
- 238000000199 molecular distillation Methods 0.000 claims description 3
- 239000011552 falling film Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 4
- 238000000926 separation method Methods 0.000 abstract description 4
- 238000004821 distillation Methods 0.000 abstract description 3
- 239000013067 intermediate product Substances 0.000 abstract 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000007872 degassing Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000000526 short-path distillation Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- RMZAYIKUYWXQPB-UHFFFAOYSA-N trioctylphosphane Chemical compound CCCCCCCCP(CCCCCCCC)CCCCCCCC RMZAYIKUYWXQPB-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/34—Separation; Purification; Stabilisation; Use of additives
- C07C41/40—Separation; Purification; Stabilisation; Use of additives by change of physical state, e.g. by crystallisation
- C07C41/42—Separation; Purification; Stabilisation; Use of additives by change of physical state, e.g. by crystallisation by distillation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
- C07C41/22—Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of halogens; by substitution of halogen atoms by other halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- the present invention relates to a process for preparing a specific ⁇ -chiral chloromethyl compound in pure or enriched form by distillative separation of said compound from mixtures containing this compound and higher-boiling impurities.
- the subject ⁇ -chiral chloromethyl compound is in crystalline form at room temperature and is a central intermediate for the preparation of a class of drugs.
- EP 0 678 503 describes ⁇ -amino-Y-hydroxy- ⁇ -aryl-alkenecarboxamides which have renin-inhibiting properties and can be used as anti-hypertensive agents in pharmaceutical preparations.
- WO 01/09083 describes a process for the preparation of said ⁇ -amino- ⁇ -hydroxy- ⁇ -aryl-alkencarboxamide.
- the central intermediate is the compound of the formula (Ia)
- chlorinating reagents carbon tetrachloride and trioctylphosphine are used.
- the resulting reaction product is purified by extractive workup first by flash chromatography and then by crystallization from hexane at -50 ° C.
- the object of the present invention was thus to provide a process for the preparation of the compound of formula (I) in pure or enriched form, which does not have the disadvantages mentioned above and makes the compound of formula (I) available in high yield and purity.
- Particularly suitable mixtures of substances to be used according to the invention are those which contain from about 25 to about 99% by weight, preferably from about 50 to about 98% by weight, more preferably from about 75 to about 97% by weight, even more preferably from about 85% to about 97%, and most preferably from about 90% to about 97%, by weight of the compound of formula (I) or the compound of formula (Ia).
- the abovementioned mixtures also contain higher-boiling impurities and, if appropriate, even lower-boiling impurities, for example solvent residues or low molecular weight by-products of the preceding synthesis stages.
- the process according to the invention serves to prepare optically active compounds of the formula (I) or (Ia) in pure or enriched form.
- the term in pure or enriched form means either that the compound of the formula (I) or (Ia) is obtained in pure form or is obtained in the form of a substance mixture which has a higher content of the respective compound of the formula (I) or (Ia), as the substance mixtures used in the invention.
- the compound of the formula (I) or (Ia) in pure form is understood to mean the particular compound having a purity of at least about 98% by weight, preferably about 99.5 to about 99.9% by weight.
- the compound of the formula (I) or (Ia) in enriched form is preferably to be understood as meaning mixtures of substances which are from about 90 to about 99.9% by weight, preferably from about 95 to about 99.9 Wt .-%, particularly preferably from about 95 to about 99.9 wt .-% and most preferably from about 97 to about 99.9 wt .-% of the compound of formula (I) or (Ia) consists ,
- the pure or enriched compounds of the formula (I) or (Ia) are obtained in optically active form.
- the enantiomeric excess of the respective compound of the formula (I) or (Ia) obtained preferably corresponds largely to that of the compound of the formula (I) or (Ia) used in the substance mixture used according to the invention.
- the compound of the formula (I) or (Ia) is preferably obtained in pure or enriched form with an enantiomeric excess which is at least 85%, more preferably at least 90%, most preferably at least 95% of the enantiomeric excess of the compound of the formula (I ) or (Ia) is.
- the process according to the invention is preferably carried out such that the distillative separation is carried out at a pressure in the range from about 0.0001 mbar to about 10 mbar, preferably from about 0.001 to about 5 mbar, and more preferably from about 0.001 to about 0.1 mbar.
- the distillative separation according to the invention can, depending on the selected pressure, be carried out at temperatures in the range of about 50.degree. C. to about 250.degree. C., preferably about 80 to about 220.degree.
- the separation according to the invention is preferably carried out in the form of a continuous distillation.
- Particularly preferred embodiments of the method according to the invention are so-called short-path or molecular distillation in which the paths between the evaporator surfaces and the condenser surfaces are as short and straight as possible.
- Suitable evaporators are in particular short-path evaporator, thin-film evaporator or falling-film evaporator.
- commercially available molecular distillation apparatuses such as those offered by specialist dealers. Alternatively, a rectification in the fine vacuum range is possible.
- the process according to the invention allows the preparation of the compound of the formula (I) or (Ia) in pure or enriched form. Accordingly, the present invention also relates to a process for purifying the compound of the formula (I) or (Ia) by distillative removal of the compound of the formula (I) from mixtures comprising the optically active compound of the formula (I) and relatively high-boiling impurities.
- the mixtures of substances to be used according to the invention may also contain lower-boiling compounds, ie compounds which have a lower boiling point than the compound of the formula (I) or (Ia).
- lower-boiling compounds for example solvent residues, excess reagents or low molecular weight by-products of the preceding synthesis steps, can be obtained as prefractions within the scope of the distillative separation according to the invention and thus also be separated from the compound of formula (I) or (Ia).
- the term higher-boiling impurities is to be understood as meaning those compounds which have a higher boiling point than the compound of the formula (I) or (Ia).
- the above-mentioned higher-boiling compounds can also be by-products of the synthesis sequence for the preparation of the compound of the formula (I).
- the mixtures of substances to be used according to the invention can be dimerization products of the compound of the formula (I), for example the compound of the formula (III)
- higher-boiling dimerization products are, for example, those in which the two halves of the molecule are linked to one another via the aromatic compounds by a disulphide bridge.
- the present invention therefore relates to the process described above, which is characterized in that use is made of mixtures which are obtainable by reacting an optically active alcohol of the formula (M)
- the present invention relates to a process for preparing optically active compounds of the formula (I)
- step b) distillative separation of the compound of the formula (I) from the mixtures of substances obtained in step a) containing the optically active compound of the formula (I) and higher-boiling impurities.
- the present invention also relates to a process for the preparation of the compound of the formula (I) or (Ia) by reacting the compound of the formula (II) or (IIa) with thionyl chloride and N, N-dimethylformamide.
- the optically active compound of the formula (II) and thionyl chloride preferably in a molar ratio in the range of about 1 to 1 to about 1 to 5, more preferably from about 1 to 1, 1 to about 1 to 2.
- the reaction is carried out in the presence of N, N-dimethylformamide, wherein N, N-dimethylformamide and thionyl chloride are preferably used in a molar ratio in the range of about 0.01 to 1 to about 1 to 1, particularly preferably in the range of about 0, 03 to 1 to 0.1 to 1.
- the reaction is preferably carried out by halogenating a solution of the optically active alcohol of the formula (II) in a suitable solvent which is inert under the reaction conditions, for example benzene, toluene, xylenes, ethers such as diethyl ether, THF, dioxane and the like Solvents, such as methylene chloride, chloroform, 1, 2-dichloroethane and the like more, preferably in toluene, together with the selected amount of N, N-dimethylformamide presents and the selected amount of thionyl chloride at a temperature of about 80 to about 100 ° C added.
- the reaction is usually completed after about one to about 5 hours, often after about 2 hours.
- the process according to the invention for the preparation of the compound of the formula (I) or (Ia) in pure or enriched form provides an unexpectedly efficient access to said compound, especially to the compound of the formula (Ia) in a form which satisfies the requirements of a drug intermediate are to take into account. It is clearly superior to the known processes for purifying the compounds mentioned by crystallization, in particular with regard to the number of process steps and the yield and purity of the product, since especially higher-boiling, structurally similar impurities with a high tendency to crystallize are insufficiently separated from the desired product by conventional crystallization ,
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention relates to a method for producing a specific a-chiral chloromethyl compound in a pure or enriched form by separation by distillation of the cited compound from mixtures containing this compound and high-boiling impurities. Said a-chiral chloromethyl compound is in a crystalline form at room temperature and represents a central intermediate product for producing a category of medicaments.
Description
Verfahren zur Herstellung einer α-chiralen Chlormethylverbindung in reiner FormProcess for the preparation of an α-chiral chloromethyl compound in pure form
Technisches Gebiet der Erfindung:Technical field of the invention:
Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung einer speziellen α- chiralen Chlormethylverbindung in reiner oder angereicherter Form durch destillative Abtrennung der genannten Verbindung aus Stoffgemischen, die diese Verbindung sowie höhersiedende Verunreinigungen enthalten. Die betreffende α-chirale Chlorme- thylverbindung liegt bei Raumtemperatur in kristalliner Form vor und stellt ein zentrales Zwischenprodukt zur Herstellung einer Klasse von Arzneimitteln dar.The present invention relates to a process for preparing a specific α-chiral chloromethyl compound in pure or enriched form by distillative separation of said compound from mixtures containing this compound and higher-boiling impurities. The subject α-chiral chloromethyl compound is in crystalline form at room temperature and is a central intermediate for the preparation of a class of drugs.
In der EP 0 678 503 werden δ-Amino-Y-hydroxy-ω-aryl-alkencarboxamide beschrieben, die Renin-inhibierende Eigenschaften aufweisen und als antihypertensive Mittel in pharmazeutischen Zubereitungen verwendet werden können.EP 0 678 503 describes δ-amino-Y-hydroxy-ω-aryl-alkenecarboxamides which have renin-inhibiting properties and can be used as anti-hypertensive agents in pharmaceutical preparations.
Die WO 01/09083 beschreibt ein Verfahren zur Herstellung der genannten δ-Amino-γ- hydroxy-ω-aryl-alkencarboxamide. Als zentrales Intermediat wird dabei die Verbindung der Formel (Ia)WO 01/09083 describes a process for the preparation of said δ-amino-γ-hydroxy-ω-aryl-alkencarboxamide. The central intermediate is the compound of the formula (Ia)
genannt. Diese wird erhalten durch Chlorierung des entsprechenden Alkohols der Formel (IIa)called. This is obtained by chlorination of the corresponding alcohol of the formula (IIa)
wobei als Chlorierungsreagenzien Tetrachlorkohlenstoff und Trioctylphosphin eingesetzt werden. Das erhaltene Reaktionsprodukt wird nach extraktiver Aufarbeitung zu- nächst durch Flash-Chromatographie und anschließend durch Kristallisation aus Hexan bei -50°C gereinigt.wherein as chlorinating reagents carbon tetrachloride and trioctylphosphine are used. The resulting reaction product is purified by extractive workup first by flash chromatography and then by crystallization from hexane at -50 ° C.
H. Rüeger et al. beschreiben in Tetrahedron Letters 41 (2000) 10085-10089 die Herstellung der Verbindung der Formel (Ia) durch Umsetzung der Verbindung der Formel (IIa) mit Thionylchlorid in Gegenwart von Pyridin und Chloroform als Lösungsmittel mit einer Ausbeute von 70%.
D.A. Sandham et al. beschreiben in Tetrahedron Letters 41 (2000) 10091-10094 die Herstellung der Verbindung der Formel (Ia) durch Umsetzung der Verbindung der Formel (IIa) mit Phosphorylchlorid in Gegenwart von DMF und Toluol als Lösungsmittel mit einer Ausbeute von 78%.H. Rüeger et al. describe in Tetrahedron Letters 41 (2000) 10085-10089 the preparation of the compound of the formula (Ia) by reacting the compound of the formula (IIa) with thionyl chloride in the presence of pyridine and chloroform as solvent in a yield of 70%. DA Sandham et al. describe in Tetrahedron Letters 41 (2000) 10091-10094 the preparation of the compound of formula (Ia) by reacting the compound of formula (IIa) with phosphoryl chloride in the presence of DMF and toluene as solvent in a yield of 78%.
Vor dem Hintergrund der an ein wirtschaftliches und in technischem Maßstab durchzuführendes Verfahren zur Herstellung eines Arzneimittelzwischenproduktes zu stellenden Anforderungen kann das dargestellte Verfahren nicht als zufriedenstellend betrachtet werden. Insbesondere die Verwendung toxischer Reagenzien sowie die auf- wendige mehrstufige Reinigung des Rohproduktes sind hierbei problematisch.In view of the commercial and industrial scale process of preparing a drug precursor, the presented process can not be considered satisfactory. In particular, the use of toxic reagents and the elaborate multi-stage purification of the crude product are problematic.
Aufgabe der Erfindung:Object of the invention:
Aufgabe der vorliegenden Erfindung war also die Bereitstellung eines Verfahrens zur Herstellung der Verbindung der Formel (I) in reiner oder angereicherter Form, die die vorstehend genannten Nachteile nicht aufweist und die Verbindung der Formel (I) in hoher Ausbeute und Reinheit zugänglich macht.The object of the present invention was thus to provide a process for the preparation of the compound of formula (I) in pure or enriched form, which does not have the disadvantages mentioned above and makes the compound of formula (I) available in high yield and purity.
Beschreibung der Erfindung sowie der bevorzugten Ausführungsformen:DESCRIPTION OF THE INVENTION AND THE PREFERRED EMBODIMENTS
Die Aufgabe wurde erfindungsgemäß gelöst, durch die Bereitstellung eines Verfahrens zur Herstellung optisch aktiver Verbindungen der Formel (I)The object has been achieved according to the invention by providing a process for preparing optically active compounds of the formula (I)
in reiner oder angereicherter Form durch destillative Abtrennung der Verbindung der Formel (I) aus Stoffgemischen enthaltend die optisch aktive Verbindung der Formel (I) und höhersiedende Verunreinigungen.in pure or enriched form by distillative separation of the compound of formula (I) from mixtures of substances containing the optically active compound of the formula (I) and higher-boiling impurities.
Das erfindungsgemäße Verfahren eignet sich insbesondere zur Herstellung der Verbindung der Formel (Ia)The process according to the invention is particularly suitable for the preparation of the compound of the formula (Ia)
in reiner oder angereicherter Form durch destillative Abtrennung der Verbindung der Formel (Ia) aus Stoffgemischen enthaltend die optisch aktive Verbindung der Formel (Ia) und höhersiedende Verunreinigungen.
Als erfindungsgemäß einzusetzende Stoffgemische eignen sich insbesondere solche, die zu etwa 25 bis etwa 99 Gew.-%, bevorzugt zu etwa 50 bis etwa 98 Gew.-%, besonders bevorzugt zu etwa 75 bis etwa 97 Gew.-%, noch mehr bevorzugt zu etwa 85 bis etwa 97 Gew.-% und am meisten bevorzugt zu etwa 90 bis etwa 97 Gew.-% aus der Verbindung der Formel (I) bzw. der Verbindung der Formel (Ia) bestehen.in pure or enriched form by distillative separation of the compound of formula (Ia) from mixtures of substances containing the optically active compound of formula (Ia) and higher boiling impurities. Particularly suitable mixtures of substances to be used according to the invention are those which contain from about 25 to about 99% by weight, preferably from about 50 to about 98% by weight, more preferably from about 75 to about 97% by weight, even more preferably from about 85% to about 97%, and most preferably from about 90% to about 97%, by weight of the compound of formula (I) or the compound of formula (Ia).
Die genannten Stoffgemische enthalten neben der in reiner oder angereicherter Form herzustellenden Verbindung der Formel (I) bzw. (Ia) noch höhersiedende Verunreini- gungen und gegebenenfalls auch noch tiefersiedende Verunreinigungen wie beispielsweise Lösemittelrückstände oder niedermolekulare Nebenprodukte der vorangegangenen Synthesestufen.In addition to the compound of the formula (I) or (Ia) to be prepared in pure or enriched form, the abovementioned mixtures also contain higher-boiling impurities and, if appropriate, even lower-boiling impurities, for example solvent residues or low molecular weight by-products of the preceding synthesis stages.
Das erfindungsgemäße Verfahren dient zur Herstellung von optisch aktiven Verbin- düngen der Formel (I) bzw. (Ia) in reiner oder angereicherter Form. Der Begriff in reiner oder angereicherter Form bedeutet dabei entweder, dass die Verbindung der Formel (I) bzw. (Ia) in reiner Form erhalten wird oder in Form eines Stoffgemisches erhalten wird, das einen höheren Gehalt an der jeweiligen Verbindung der Formel (I) bzw. (Ia) aufweist, als die erfindungsgemäß eingesetzten Stoffgemische.The process according to the invention serves to prepare optically active compounds of the formula (I) or (Ia) in pure or enriched form. The term in pure or enriched form means either that the compound of the formula (I) or (Ia) is obtained in pure form or is obtained in the form of a substance mixture which has a higher content of the respective compound of the formula (I) or (Ia), as the substance mixtures used in the invention.
Unter der Verbindung der Formel (I) bzw. (Ia) in reiner Form ist dabei die jeweilige Verbindung mit einer Reinheit von mindestens etwa 98 Gew.-%, bevorzugt etwa 99,5 bis etwa 99,9 Gew.-% zu verstehen. Unter der Verbindung der Formel (I) bzw. (Ia) in angereicherter Form sind im Rahmen der vorliegenden Erfindung bevorzugt Stoffgemische zu verstehen, die zu etwa 90 bis etwa 99,9 Gew.-%, bevorzugt von etwa 95 bis etwa 99,9 Gew.-%, besonders bevorzugt von etwa 95 bis etwa 99,9 Gew.-% und ganz besonders bevorzugt zu etwa 97 bis etwa 99,9 Gew.-% aus der Verbindung der Formel (I) bzw. (Ia), besteht.The compound of the formula (I) or (Ia) in pure form is understood to mean the particular compound having a purity of at least about 98% by weight, preferably about 99.5 to about 99.9% by weight. For the purposes of the present invention, the compound of the formula (I) or (Ia) in enriched form is preferably to be understood as meaning mixtures of substances which are from about 90 to about 99.9% by weight, preferably from about 95 to about 99.9 Wt .-%, particularly preferably from about 95 to about 99.9 wt .-% and most preferably from about 97 to about 99.9 wt .-% of the compound of formula (I) or (Ia) consists ,
Die reinen oder angereicherten Verbindungen der Formel (I) bzw. (Ia) werden in optisch aktiver Form erhalten. Dabei entspricht der Enantiomerenüberschuss der jeweiligen erhaltenen Verbindung der Formel (I) bzw. (Ia) bevorzugt weitgehend dem der im erfindungsgemäß eingesetzten Stoffgemisch enthaltenen Verbindung der Formel (I) bzw. (Ia). Bevorzugt erhält man die Verbindung der Formel (I) bzw. (Ia) in reiner oder angereicherter Form mit einem Enantiomerenüberschuss, der mindestens 85%, besonders bevorzugt mindestens 90%, ganz besonders bevorzugt mindestens 95% des Enantiomerenüberschusses der eingesetzten Verbindung der Formel (I) bzw. (Ia) beträgt.The pure or enriched compounds of the formula (I) or (Ia) are obtained in optically active form. In this case, the enantiomeric excess of the respective compound of the formula (I) or (Ia) obtained preferably corresponds largely to that of the compound of the formula (I) or (Ia) used in the substance mixture used according to the invention. The compound of the formula (I) or (Ia) is preferably obtained in pure or enriched form with an enantiomeric excess which is at least 85%, more preferably at least 90%, most preferably at least 95% of the enantiomeric excess of the compound of the formula (I ) or (Ia) is.
Das erfindungsgemäße Verfahren wird vorzugsweise so durchgeführt, dass man die destillative Abtrennung bei einem Druck im Bereich von etwa 0,0001 mbar bis etwa 10
mbar, bevorzugt von etwa 0,001 bis etwa 5 mbar und besonders bevorzugt von etwa 0,001 bis etwa 0,1 mbar durchführt.The process according to the invention is preferably carried out such that the distillative separation is carried out at a pressure in the range from about 0.0001 mbar to about 10 mbar, preferably from about 0.001 to about 5 mbar, and more preferably from about 0.001 to about 0.1 mbar.
Die erfindungsgemäße destillative Abtrennung kann, in Abhängigkeit vom gewählten Druck, bei Temperaturen im Bereich von etwa 50°C bis etwa 250°C, bevorzugt etwa 80 bis etwa 220°C durchgeführt werden.The distillative separation according to the invention can, depending on the selected pressure, be carried out at temperatures in the range of about 50.degree. C. to about 250.degree. C., preferably about 80 to about 220.degree.
Die erfindungsgemäße Abtrennung der Verbindung der Formel (I) bzw. (Ia) kann in einer Vielzahl von dem Fachmann bekannten Ausgestaltungen durchgeführt werden, wie sie beispielsweise in Handbüchern der chemischen Technik wie Ullmann oderThe separation according to the invention of the compound of the formula (I) or (Ia) can be carried out in a multiplicity of embodiments known to the person skilled in the art, as described, for example, in manuals of the chemical technology such as Ullmann or
Winnacker-Küchler ausführlich beschrieben sind. Bevorzugt führt man die erfindungsgemäße Abtrennung in Form einer kontinuierlichen Destillation durch.Winnacker-Küchler are described in detail. The separation according to the invention is preferably carried out in the form of a continuous distillation.
Besonders bevorzugte Ausgestaltungen des erfindungsgemäßen Verfahrens sind so- genannte Kurzweg- oder Molekulardestillationen, bei denen mit möglichst kurzen und geradlinig verlaufenden Wegen zwischen Verdampfer- und Kondensatorflächen gearbeitet wird. Geeignete Verdampfer sind insbesondere Kurzwegverdampfer, Dünnschichtverdampfer oder Fallstromverdampfer. Besonders gut eignen sich auch kommerziell erhältliche Molekulardestillationsapparate, wie sie im Fachhandel angeboten werden. Alternativ ist auch eine Rektifikation im Feinvakuumbereich möglich.Particularly preferred embodiments of the method according to the invention are so-called short-path or molecular distillation in which the paths between the evaporator surfaces and the condenser surfaces are as short and straight as possible. Suitable evaporators are in particular short-path evaporator, thin-film evaporator or falling-film evaporator. Also particularly suitable are commercially available molecular distillation apparatuses, such as those offered by specialist dealers. Alternatively, a rectification in the fine vacuum range is possible.
Dabei ist es auch möglich, mehrere der genannten Vorrichtungen hintereinander zu betreiben, beispielsweise um zunächst gegebenenfalls noch vorhandene flüchtige Verunreinigungen bzw. tiefersiedende Verunreinigungen abzutrennen. Es hat sich als vor- teilhaft erwiesen, vor der destillativen Abtrennung der gewünschten Verbindung eine Entgasung des eingesetzten Stoffgemisches vorzunehmen.It is also possible to operate a plurality of said devices in succession, for example, first to optionally separate any remaining volatile impurities or lower-boiling impurities. It has proved to be advantageous to carry out a degassing of the substance mixture used before the distillative removal of the desired compound.
Das erfindungsgemäße Verfahren erlaubt die Herstellung der Verbindung der Formel (I) bzw. (Ia) in reiner oder angereicherter Form. Die vorliegende Erfindung betrifft dem- gemäß auch ein Verfahren zur Reinigung der Verbindung der Formel (I) oder (Ia) durch destillative Abtrennung der Verbindung der Formel (I) aus Stoffgemischen enthaltend die optisch aktive Verbindung der Formel (I) und höhersiedende Verunreinigungen.The process according to the invention allows the preparation of the compound of the formula (I) or (Ia) in pure or enriched form. Accordingly, the present invention also relates to a process for purifying the compound of the formula (I) or (Ia) by distillative removal of the compound of the formula (I) from mixtures comprising the optically active compound of the formula (I) and relatively high-boiling impurities.
Zusätzlich zu den genannten höhersiedenden Verunreinigungen können die erfin- dungsgemäß einzusetzenden Stoffgemische auch tiefersiedende Verbindungen, d.h. Verbindungen, die einen niedrigeren Siedepunkt als die Verbindung der Formel (I) bzw. (Ia) aufweisen, enthalten. Diese tiefersiedenden Verbindungen, beispielsweise Lösemittelrückstände, überschüssige Reagenzien oder niedermolekulare Nebenprodukte der vorangegangenen Synthesestufen, können im Rahmen der erfindungsgemäßen destillativen Abtrennung als Vorfraktionen erhalten und so ebenfalls von der Verbindung der Formel (I) bzw. (Ia) abgetrennt werden.
Unter dem Begriff höhersiedende Verunreinigungen sind im Rahmen der vorliegenden Erfindung solche Verbindungen zu verstehen, die einen höheren Siedepunkt als die Verbindung der Formel (I) bzw. (Ia) aufweisen. Auch die genannten höhersiedenden Verbindungen können Nebenprodukte der Synthesesequenz zur Herstellung der Verbindung der Formel (I) darstellen. Beispielsweise können die erfindungsgemäß einzusetzenden Stoffgemische Dimerisierungsprodukte der Verbindung der Formel (I) wie beispielsweise die Verbindung der Formel (IM)In addition to the higher-boiling impurities mentioned, the mixtures of substances to be used according to the invention may also contain lower-boiling compounds, ie compounds which have a lower boiling point than the compound of the formula (I) or (Ia). These lower-boiling compounds, for example solvent residues, excess reagents or low molecular weight by-products of the preceding synthesis steps, can be obtained as prefractions within the scope of the distillative separation according to the invention and thus also be separated from the compound of formula (I) or (Ia). In the context of the present invention, the term higher-boiling impurities is to be understood as meaning those compounds which have a higher boiling point than the compound of the formula (I) or (Ia). The above-mentioned higher-boiling compounds can also be by-products of the synthesis sequence for the preparation of the compound of the formula (I). For example, the mixtures of substances to be used according to the invention can be dimerization products of the compound of the formula (I), for example the compound of the formula (III)
enthalten. Weitere mögliche höhersiedende Dimerisierungsprodukte sind beispielsweise solche, bei denn die beiden Molekülhälften über die Aromaten durch eine Disul- fidbrücke miteinander verknüpft sind.contain. Further possible higher-boiling dimerization products are, for example, those in which the two halves of the molecule are linked to one another via the aromatic compounds by a disulphide bridge.
Derartige höhersiedende Verunreinigungen entstehen in geringem Ausmaß beispielsweise bei der Herstellung der Verbindung der Formel (I) in optisch aktiver Form durch Umsetzung eines optisch aktiven Alkohols der Formel (M)Such higher-boiling impurities arise to a slight extent, for example in the preparation of the compound of formula (I) in optically active form by reacting an optically active alcohol of the formula (M)
mit Thionylchlorid und N,N-Dimethylformamid.with thionyl chloride and N, N-dimethylformamide.
Im Rahmen einer bevorzugten Ausführungsform betrifft die vorliegende Erfindung daher das vorstehend beschriebene Verfahren, das dadurch gekennzeichnet ist, dass man Stoffgemische einsetzt, die erhältlich sind durch Umsetzung eines optisch aktiven Alkohols der Formel (M)In a preferred embodiment, the present invention therefore relates to the process described above, which is characterized in that use is made of mixtures which are obtainable by reacting an optically active alcohol of the formula (M)
mit Thionylchlorid und N,N-Dimethylformamid. Demgemäß betrifft die vorliegende Erfindung ein Verfahren zur Herstellung optisch aktiver Verbindungen der Formel (I)with thionyl chloride and N, N-dimethylformamide. Accordingly, the present invention relates to a process for preparing optically active compounds of the formula (I)
in reiner oder angereicherter Form umfassend die Schritte in pure or enriched form comprising the steps
a) Umsetzung eines optisch aktiven Alkohols der Formel (II)a) reaction of an optically active alcohol of the formula (II)
bzw. (IIa) mit Thionylchlorid und N,N-Dimethylformamid unter Erhalt der Verbindung der Formel (I) bzw. (Ia) undor (IIa) with thionyl chloride and N, N-dimethylformamide to give the compound of the formula (I) or (Ia) and
b) destillative Abtrennung der Verbindung der Formel (I) aus den in Schritt a) erhaltenen Stoffgemischen enthaltend die optisch aktive Verbindung der Formel (I) und höhersiedende Verunreinigungen.b) distillative separation of the compound of the formula (I) from the mixtures of substances obtained in step a) containing the optically active compound of the formula (I) and higher-boiling impurities.
Die vorliegende Erfindung betrifft auch ein Verfahren zur Herstellung der Verbindung der Formel (I) bzw. (Ia) durch Umsetzung der Verbindung der Formel (II) bzw. (IIa) mit Thionylchlorid und N,N-Dimethylformamid.The present invention also relates to a process for the preparation of the compound of the formula (I) or (Ia) by reacting the compound of the formula (II) or (IIa) with thionyl chloride and N, N-dimethylformamide.
Im Rahmen des erfindungsgemäßen Verfahrens zur Herstellung der Verbindung der Formel (I) in optisch aktiver Form durch Umsetzung der Verbindung der Formel (II) in optisch aktiver Form setzt man die optisch aktive Verbindung der Formel (II) und Thionylchlorid, vorzugsweise in einem molaren Verhältnis im Bereich von etwa 1 zu 1 bis etwa 1 zu 5, besonders bevorzugt von etwa 1 zu 1 ,1 bis etwa 1 zu 2, um.In the context of the process according to the invention for preparing the compound of the formula (I) in optically active form by reacting the compound of the formula (II) in optically active form, the optically active compound of the formula (II) and thionyl chloride, preferably in a molar ratio in the range of about 1 to 1 to about 1 to 5, more preferably from about 1 to 1, 1 to about 1 to 2.
Die Umsetzung wird in Gegenwart von N,N-Dimethylformamid durchgeführt, wobei man N,N-Dimethylformamid und Thionylchlorid bevorzugt in einem molaren Verhältnis im Bereich von etwa 0,01 zu 1 bis etwa 1 zu 1 , besonders bevorzugt im Bereich von etwa 0,03 zu 1 bis 0,1 zu 1 einsetzt.The reaction is carried out in the presence of N, N-dimethylformamide, wherein N, N-dimethylformamide and thionyl chloride are preferably used in a molar ratio in the range of about 0.01 to 1 to about 1 to 1, particularly preferably in the range of about 0, 03 to 1 to 0.1 to 1.
Die Umsetzung wird vorzugsweise so durchgeführt, dass man eine Lösung des optisch aktiven Alkohols der Formel (II) in einem geeigneten, unter den Reaktionsbedingungen inerten Lösungsmittel wie beispielsweise Benzol, Toluol, Xylolen, Ethern wie z.B. Diethylether, THF, Dioxan und dergleichen mehr, halogenierten Lösungsmitteln, wie z.B. Methylenchlorid, Chloroform, 1 ,2-Dichlorethan und dergleichen mehr, bevorzugt in Toluol, zusammen mit der gewählten Menge N,N-Dimethylformamid vorlegt und die gewählte Menge Thionylchlorid bei einer Temperatur von etwa 80 bis etwa 100 °C zusetzt. Die Umsetzung ist üblicherweise nach etwa einer bis etwa 5 h, oft nach etwa 2 h weitgehend abgeschlossen. Nach beendeter Reaktion entfernt man überschüssi- gesThionylchlorid, vorteilhaft durch Destillation unter vermindertem Druck und neutrali- siert den Rückstand durch Zugabe einer geeigneten Base wie beispielsweise wässriger
Natronlauge oder wässrige NaHCθ3-Lösung. Die weitere Aufarbeitung des erhaltenen Reaktionsgemisches kann nach dem Fachmann bekannten Methoden vorgenommen werden.The reaction is preferably carried out by halogenating a solution of the optically active alcohol of the formula (II) in a suitable solvent which is inert under the reaction conditions, for example benzene, toluene, xylenes, ethers such as diethyl ether, THF, dioxane and the like Solvents, such as methylene chloride, chloroform, 1, 2-dichloroethane and the like more, preferably in toluene, together with the selected amount of N, N-dimethylformamide presents and the selected amount of thionyl chloride at a temperature of about 80 to about 100 ° C added. The reaction is usually completed after about one to about 5 hours, often after about 2 hours. After completion of the reaction, excess thionyl chloride is removed, advantageously by distillation under reduced pressure and the residue is neutralized by addition of a suitable base such as aqueous Sodium hydroxide solution or aqueous NaHCO 3 solution. The further work-up of the resulting reaction mixture can be carried out by methods known to the person skilled in the art.
Das erfindungsgemäße Verfahren zur Herstellung der Verbindung der Formel (I) bzw. (Ia) in reiner oder angereicherter Form eröffnet einen unerwartet leistungsfähigen Zugang zu der genannten Verbindung, speziell zur Verbindung der Formel (Ia) in einer Form, die den Anforderungen, die an ein Arzneimittel-Zwischenprodukt zu stellen sind, Rechnung trägt. Es ist den bekannten Verfahren zur Reinigung der genannten Verbin- düng durch Kristallisation insbesondere bezüglich der Anzahl der Verfahrensschritte sowie der Ausbeute und Reinheit des Produktes deutlich überlegen, da insbesondere höhersiedende, strukturell ähnliche Verunreinigungen mit hoher Kristallisationsneigung durch herkömmliche Kristallisation nur unzureichend vom gewünschten Produkt abzutrennen sind.The process according to the invention for the preparation of the compound of the formula (I) or (Ia) in pure or enriched form provides an unexpectedly efficient access to said compound, especially to the compound of the formula (Ia) in a form which satisfies the requirements of a drug intermediate are to take into account. It is clearly superior to the known processes for purifying the compounds mentioned by crystallization, in particular with regard to the number of process steps and the yield and purity of the product, since especially higher-boiling, structurally similar impurities with a high tendency to crystallize are insufficiently separated from the desired product by conventional crystallization ,
Die folgenden Beispiele dienen der Veranschaulichung der Erfindung, ohne sie in irgendeiner Form zu beschränken:The following examples serve to illustrate the invention without limiting it in any way:
Beispiel 1 :Example 1 :
In einem 1 im3 Stahlemailkessel wurden 440 kg einer etwa 29%-igen Lösung des Alkohols der Formel (II) mit einem Enantiomerenüberschuss von 99,2% ee in Toluol und 3,5 kg N,N-Dimethylformamid (DMF) eingefüllt. Bei 90 °C wurden 77 kg Thionylchlorid zudosiert, 2 Stunden nachgerührt und der Kesselinhalt auf 40 °C abgekühlt. Das überschüssige Thionylchlorid wurde im Vakuum abdestilliert. Bei 2 bis 10 °C wurde der Destillationssumpf in einem 1 m3 HC-Kessel zu 100 L einer 15%igen Natronlauge zugefahren, die wässrige Unterphase abgetrennt und die organische Oberphase mit 100 L VE-Wasser gewaschen. Man erhielt 124 kg der Verbindung der Formel (Ia) als etwa 30%ige Lösung in Toluol. Der Enantiomerenüberschuss des erhaltenen Produktes betrug 98,5 % ee.In a 1 in 3 Stahlemailkessel 440 kg of an approximately 29% solution of the alcohol of formula (II) were filled with an enantiomeric excess of 99.2% ee in toluene and 3.5 kg of N, N-dimethylformamide (DMF). At 90 ° C 77 kg of thionyl chloride were metered in, stirred for 2 hours and the contents of the kettle cooled to 40 ° C. The excess thionyl chloride was distilled off in vacuo. At 2 to 10 ° C, the distillation bottom was added in a 1 m 3 HC kettle to 100 L of a 15% sodium hydroxide solution, the aqueous lower phase separated and the organic upper phase washed with 100 L of deionized water. 124 kg of the compound of the formula (Ia) were obtained as an about 30% solution in toluene. The enantiomeric excess of the product obtained was 98.5% ee.
Beispiel 2:Example 2:
In einem 4 m3 Stahlemailkessel wurde von 1300 kg einer etwa 30%-igen Lösung der Verbindung der Formel (Ia) in Toluol das Lösungsmittel im Vakuum abdestilliert. Der verbliebene Sumpf wurde bei 50°C mit 1600 kg Methanol versetzt, auf 20 °C abgekühlt, mit Kristallen angeimpft und mit einer Rate von 10 K/h weiter auf -10 °C abge- kühlt. Die resultierende Kristallmaische wurde bei -10 °C über einen Prozessfilter abgetrennt, dreimal mit 200 kg kaltem Methanol gewaschen und im Vakuum getrocknet. Man erhielt 250 kg der Verbindung der Formel (Ia) in kristalliner Form, entsprechend
einer Ausbeute von 64%. Der Enantiomerenüberschuss betrug über 99,8 % ee. Die Analyse der Reinheit des Reaktionsprodukts erfolgte mittels HPLC nach folgender Methode:In a 4 m 3 Stahlemailkessel of 1300 kg of an approximately 30% solution of the compound of formula (Ia) in toluene, the solvent was distilled off in vacuo. The remaining bottoms were mixed at 50 ° C with 1600 kg of methanol, cooled to 20 ° C, seeded with crystals and further cooled to -10 ° C at a rate of 10 K / h. The resulting crystal mash was separated at -10 ° C via a process filter, washed three times with 200 kg of cold methanol and dried in vacuo. 250 kg of the compound of the formula (Ia) were obtained in crystalline form, correspondingly a yield of 64%. The enantiomeric excess was over 99.8% ee. The analysis of the purity of the reaction product was carried out by HPLC according to the following method:
Säule: Waters Symmetry C18 5 μm, 150 x 3 mm Eluent: A) 0,2 Vol.-% H3PO4 in Wasser; B) CH3CNColumn: Waters Symmetry C18 5 μm, 150 × 3 mm Eluent: A) 0.2% by volume H 3 PO 4 in water; B) CH 3 CN
Gradient (bezogen auf Eluent B): 0 min (45 %) 12 min (95 %) 13 min (95 %) 13,1 min (45 %)Gradient (based on eluent B): 0 min (45%) 12 min (95%) 13 min (95%) 13.1 min (45%)
Fluss: 1 ,2 ml/min, Temperatur: 60 °C, Injektionsvolumen: 5 μl Detektion: UV-Detektor bei 230 nmFlow: 1, 2 ml / min, temperature: 60 ° C, injection volume: 5 μl detection: UV detector at 230 nm
Das Material enthielt gemäß HPLC-Analyse 98,1 FI.-% der Verbindung (Ia) und 0,67 FI.-% einer höhersiedenden Nebenkomponente. Bei dieser Methode eluierte Verbindung (Ia) bei 6,61 min und die Nebenkomponente bei 11 ,89 min.The material contained, according to HPLC analysis, 98.1% by volume of compound (Ia) and 0.67 part by weight of a higher-boiling minor component. In this method eluted compound (Ia) at 6.61 min and the minor component at 11.89 min.
Beispiel 3:Example 3:
500 g des kristallisierten Materials aus Beispiel 2, enthaltend ca. 98,1 % der Verbin- düng der Formel (Ia) wurden bei 0,1 mbar und 180 °C Verdampfertemperatur an einem Kurzwegverdampfer KDL 5 der Firma UIC GmbH, Alzenau-Hörstein destilliert. Es wurden 430 g (87 % Ausbeute) hellgelbes Destillat mit einem Gehalt von über 99 % und einem Enantiomerenüberschuss von 99,8 % ee erhalten.500 g of the crystallized material from Example 2, containing about 98.1% of the compounds of the formula (Ia) were distilled at 0.1 mbar and 180 ° C evaporator temperature on a short path evaporator KDL 5 UIC GmbH, Alzenau -Hoerstein , There was obtained 430 g (87% yield) of light yellow distillate with a content of over 99% and an enantiomeric excess of 99.8% ee.
Beispiel 4:Example 4:
500 g des kristallisierten Materials aus Beispiel 2 enthaltend ca. 98,1 % der Verbindung der Formel (Ia) wurden bei 0,001 mbar und 100 °C Verdampfertemperatur an einem Kurzwegverdampfer der Firma UIC GmbH destilliert. Es wurden 456 g (92 % Ausbeute) hellgelbes Destillat mit einem Gehalt von über 99 % und einem Enantiomerenüberschuss von 99,8 % ee erhalten.500 g of the crystallized material from Example 2 containing about 98.1% of the compound of formula (Ia) were distilled at 0.001 mbar and 100 ° C evaporator temperature on a short path evaporator from UIC GmbH. There were obtained 456 g (92% yield) of light yellow distillate with a content of over 99% and an enantiomeric excess of 99.8% ee.
Beispiel 5:Example 5:
500 kg des kristallisierten Materials aus Beispiel 2, enthaltend ca. 98,1 % der Verbindung der Formel (Ia) sowie 0,67 FI.-% einer Nebenkomponente wurden dreistufig (Entgasung bei 1 mbar, 120 °C, Dünnschichtverdampfer 0,1 mbar, 120 °C, Kurzwegver- dampfer, 0,01 mbar, 140 °C) zur Abtrennung von leicht- und schwersiedenden Nebenkomponenten kontinuierlich destilliert. Die Leichtsieder wurden bei der Entgasung und Dünnschichtverdampfung abgetrennt, die Schwersieder bei der abschließenden Kurz-
wegdestillation entfernt. Es wurden 420 kg (85 % Ausbeute) hellgelbes Destillat mit einem Gehalt von 99,4 FI.-% nach der im Beispiel 2 angegebenen HPLC-Methode erhalten, bei dem die Nebenkomponente nicht mehr nachweisbar war. Der Enantiomere- nüberschuss betrug über 99,8 % ee.
500 kg of the crystallized material from Example 2, containing about 98.1% of the compound of formula (Ia) and 0.67 FI .-% of a minor component were in three stages (degassing at 1 mbar, 120 ° C, thin-film evaporator 0.1 mbar , 120 ° C, short-path evaporator, 0.01 mbar, 140 ° C) for the separation of low-boiling and high-boiling secondary components continuously distilled. The low boilers were separated during the degassing and thin-film evaporation, the high boilers at the final short run. wegdestillation removed. 420 kg (85% yield) of pale yellow distillate with a content of 99.4% by weight were obtained by the HPLC method given in Example 2, in which the secondary component was no longer detectable. The enantiomeric excess was greater than 99.8% ee.
Claims
1. Verfahren zur Herstellung optisch aktiver Verbindungen der Formel (I)1. Process for the preparation of optically active compounds of the formula (I)
in reiner oder angereicherter Form durch destillative Abtrennung der Verbindung der Formel (I) aus Stoffgemischen enthaltend die optisch aktive Verbindung der Formel (I) und höhersiedende Verunreinigungen. 0in pure or enriched form by distillative separation of the compound of formula (I) from mixtures of substances containing the optically active compound of the formula (I) and higher-boiling impurities. 0
2. Verfahren nach Anspruch 1 zur Herstellung der Verbindung der Formel (Ia)2. Process according to Claim 1 for the preparation of the compound of the formula (Ia)
5 in reiner oder angereicherter Form durch destillative Abtrennung der Verbindung der Formel (Ia) aus Stoffgemischen enthaltend die optisch aktive Verbindung der Formel (Ia) und höhersiedende Verunreinigungen.5 in pure or enriched form by distillative separation of the compound of formula (Ia) from mixtures of substances containing the optically active compound of formula (Ia) and higher boiling impurities.
3. Verfahren nach Anspruch 1 oder 2, dadurch gekennzeichnet, dass man die 0 destillative Abtrennung bei einem Druck im Bereich von 0,0001 mbar bis 10 mbar durchführt.3. The method according to claim 1 or 2, characterized in that one carries out the 0 distillative separation at a pressure in the range of 0.0001 mbar to 10 mbar.
4. Verfahren nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, dass man die destillative Abtrennung bei einer Temperatur im Bereich von 50°C bis 5 2500C durchführt.4. The method according to any one of claims 1 to 3, characterized in that one carries out the distillative separation at a temperature in the range of 50 ° C to 5 250 0 C.
5. Verfahren nach einem der Ansprüche 1 bis 4, dadurch gekennzeichnet, dass man die destillative Abtrennung in Form einer kontinuierlichen Destillation durchführt. 05. The method according to any one of claims 1 to 4, characterized in that one carries out the distillative separation in the form of a continuous distillation. 0
6. Verfahren nach Anspruch 5, dadurch gekennzeichnet, dass man die kontinuierliche Destillation in Form einer Molekulardestillation oder mittels eines Kurzwegverdampfers, Dünnschichtverdampfers oder Fallstromverdampfers oder einer Rektifikation im Feinvakuumbereich durchführt. 56. The method according to claim 5, characterized in that one carries out the continuous distillation in the form of a molecular distillation or by means of a short-path evaporator, thin-film evaporator or falling-film evaporator or a rectification in the fine vacuum range. 5
7. Verfahren nach einem der Ansprüche 1 bis 6, dadurch gekennzeichnet, dass die Stoffgemische zusätzlich tiefersiedende Verunreinigungen enthalten. 7. The method according to any one of claims 1 to 6, characterized in that the mixtures additionally contain lower-boiling impurities.
8. Verfahren nach einem der Ansprüche 1 bis 7, dadurch gekennzeichnet, dass man Stoffgemische einsetzt, die zu 25 bis 99 Gew.-% aus der Verbindung der Formel (I) bestehen.8. The method according to any one of claims 1 to 7, characterized in that one uses mixtures of substances which consist of 25 to 99 wt .-% of the compound of formula (I).
9. Verfahren nach einem der Ansprüche 1 bis 8 zur Herstellung der Verbindung der Formel (I) mit einer Reinheit von 95 bis 99,9 Gew.-%.9. The method according to any one of claims 1 to 8 for the preparation of the compound of formula (I) having a purity of 95 to 99.9 wt .-%.
10. Verfahren nach einem der Ansprüche 1 bis 9 zur Herstellung der Verbindung der Formel (I) mit einer Reinheit von 98 bis 99,9 Gew.-%.10. The method according to any one of claims 1 to 9 for the preparation of the compound of formula (I) having a purity of 98 to 99.9 wt .-%.
1 1. Verfahren nach einem der Ansprüche 1 bis 10, dadurch gekennzeichnet, dass die höhersiedenden Verunreinigungen Nebenprodukte der Synthese der Verbindung der Formel (I) darstellen.1 1. The method according to any one of claims 1 to 10, characterized in that the higher-boiling impurities are by-products of the synthesis of the compound of formula (I).
12. Verfahren nach einem der Ansprüche 1 bis 1 1 , dadurch gekennzeichnet, dass man Stoffgemische einsetzt, die erhältlich sind durch Umsetzung eines optisch aktiven Alkohols der Formel (II)12. The method according to any one of claims 1 to 1 1, characterized in that one uses mixtures which are obtainable by reacting an optically active alcohol of the formula (II)
mit Thionylchlorid und N,N-Dimethylformamid.with thionyl chloride and N, N-dimethylformamide.
13. Verfahren zur Herstellung der Verbindung der Formel (I) durch Umsetzung der Verbindung der Formel (II) mit Thionylchlorid und N,N-Dimethylformamid.13. A process for the preparation of the compound of formula (I) by reacting the compound of formula (II) with thionyl chloride and N, N-dimethylformamide.
14. Verfahren nach Anspruch 13, dadurch gekennzeichnet, dass man die Verbindung der Formel (I) und Thionylchlorid in einem molaren Verhältnis im Bereich von 1 zu 1 bis 1 zu 5 einsetzt.14. The method according to claim 13, characterized in that one uses the compound of formula (I) and thionyl chloride in a molar ratio in the range of 1 to 1 to 1 to 5.
15. Verfahren nach Anspruch 13 oder 14, dadurch gekennzeichnet, dass man Thionylchlorid und N,N-Dimethylformamid in einem molaren Verhältnis im Bereich von 1 zu 0,01 bis 1 zu 1 einsetzt. 15. The method according to claim 13 or 14, characterized in that one uses thionyl chloride and N, N-dimethylformamide in a molar ratio in the range of 1 to 0.01 to 1 to 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06841346A EP1966113A1 (en) | 2005-12-23 | 2006-12-13 | Method for producing an alpha-chiral chloromethyl compound in a pure form |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05112933 | 2005-12-23 | ||
EP06841346A EP1966113A1 (en) | 2005-12-23 | 2006-12-13 | Method for producing an alpha-chiral chloromethyl compound in a pure form |
PCT/EP2006/069632 WO2007074062A1 (en) | 2005-12-23 | 2006-12-13 | Method for producing an alpha-chiral chloromethyl compound in a pure form |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1966113A1 true EP1966113A1 (en) | 2008-09-10 |
Family
ID=37951840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06841346A Withdrawn EP1966113A1 (en) | 2005-12-23 | 2006-12-13 | Method for producing an alpha-chiral chloromethyl compound in a pure form |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080306311A1 (en) |
EP (1) | EP1966113A1 (en) |
JP (1) | JP2009520753A (en) |
CN (1) | CN101346333A (en) |
WO (1) | WO2007074062A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201202178A (en) | 2010-06-04 | 2012-01-16 | Chemo Iberica Sa | Process for producing Aliskiren |
IT1400961B1 (en) * | 2010-06-04 | 2013-07-05 | Chemo Iberica Sa | ALISKIREN PRODUCTION PROCESS |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US700978A (en) * | 1902-02-20 | 1902-05-27 | Isaac E Palmer | Hammock. |
JP2727688B2 (en) * | 1989-09-22 | 1998-03-11 | 住友化学工業株式会社 | Optically active benzyl derivatives and their preparation |
US5606078A (en) * | 1994-04-18 | 1997-02-25 | Ciba-Geigy Corporation | 3,5-Disubstituted tetrahydrofuran-2-ones |
IT1276165B1 (en) * | 1995-11-24 | 1997-10-27 | Caffaro Spa Ind Chim | PROCEDURE FOR ENANTIOSELECTIVE SYNTHESIS OF CHIRAL DERIVATIVES OF S-3- (4'-TERT-BUTYL) -PHENYL-2-METHYL PROPYLAMINE, SYSTEMIC FUNGICIDES |
JP3915253B2 (en) * | 1998-06-12 | 2007-05-16 | 三菱化学株式会社 | Method for producing ω-halogenoalkylstyrene derivative |
DE122007000077I2 (en) * | 2000-07-25 | 2008-08-21 | Speedel Pharma Ag Hirchgaessle | METHOD FOR THE PRODUCTION OF SUBSTITUTED OCTANOYL AMIDES |
-
2006
- 2006-12-13 CN CNA2006800489454A patent/CN101346333A/en active Pending
- 2006-12-13 US US12/158,543 patent/US20080306311A1/en not_active Abandoned
- 2006-12-13 EP EP06841346A patent/EP1966113A1/en not_active Withdrawn
- 2006-12-13 WO PCT/EP2006/069632 patent/WO2007074062A1/en active Application Filing
- 2006-12-13 JP JP2008546386A patent/JP2009520753A/en active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO2007074062A1 * |
Also Published As
Publication number | Publication date |
---|---|
CN101346333A (en) | 2009-01-14 |
WO2007074062A1 (en) | 2007-07-05 |
US20080306311A1 (en) | 2008-12-11 |
JP2009520753A (en) | 2009-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0072514B1 (en) | Process for the halogenation of organic compounds | |
DE4100441A1 (en) | PROCESS FOR PREPARING 6,12-DIHYDRO-6-HYDROXY-CANNABIDIOL AND USE THEREOF FOR THE PREPARATION OF TRANS-DELTA-9-TETRAHYDROCANNABINOL | |
EP2200961A1 (en) | Continuous process for preparing menthol in pure or enriched form | |
EP0026311B2 (en) | Process for preparing very pure epsilon-caprolactone | |
EP1966113A1 (en) | Method for producing an alpha-chiral chloromethyl compound in a pure form | |
DE2607294C2 (en) | Process for the preparation of 2-amino-1-butanol | |
WO2009003796A1 (en) | Method for the synthesis of neral by the isomerization of isocitrals | |
DE69219582T2 (en) | NEW CONNECTION AND SEPARATORY REPUBLIC | |
DE112020004177B4 (en) | PROCESS FOR PREPARING THE SODIUM SALT OF 4-[[(1R)-2-[5-(2-FLUORO-3-METHOXYPHENYL)-3-[[2-FLUORO-6-(TRIFLUOROMETHYL)-PHENYL]METHYL]-3,6-DIHYDRO-4-METHYL-2,6-DIOXO-1(2H)-PYRIMIDINYL]-1-PHENYLETHYL]AMINO]BUTANAIC ACID (ELAGOLIX SODIUM SALT) AND INTERMEDIATE STAGES OF THIS PROCESS | |
EP0057844A1 (en) | Process for the preparation of polychlorobenzoyl chlorides | |
WO2002042286A1 (en) | Method for continuously acylating chromanol ester derivatives | |
DE3802619C1 (en) | ||
DE69903498T2 (en) | Process for the preparation of 13-cis-retinoic acid | |
EP1999102B1 (en) | Process for preparing n,n-dimethylaminoethoxyethanol | |
DE69814462T2 (en) | 1,7-DIBROMODIBENZOSUBERONE AND PRODUCTION METHOD | |
EP0192148B1 (en) | 2,4-dichlorothiazole derivatives and process for their preparation | |
EP0224902B1 (en) | Process for the preparation of d-threo-1(p-methylsulfonylphenyl)-2-dichloracetamido-propandiol-1,3-(thiamphenicol)and use of suitable intermediate products | |
DE69117137T2 (en) | 2-chloropropionaldehyde trimer and process for its preparation | |
EP1204628A1 (en) | Method for producing phthalic anhydride according to specifications | |
EP0936220A1 (en) | Method for the catalytic preparation of 3-isochromanones from phthalanes | |
DE3607993A1 (en) | METHOD FOR PRODUCING DIAZIRIDINES AND PRODUCTS THEREOF | |
EP0261388B1 (en) | Process for the separation of diastereomers of cyclopropanecarboxylic-acid esters | |
DE3842029A1 (en) | 2-(3'-Halo-n-propyl)-2,5,7,8-tetramethyl-6-chromanols, process for their preparation, and intermediates of this process | |
DE2950436A1 (en) | 1 ALPHA -AETHYL-1 BETA - SQUARE CLAMP ON 2 '- (METHOXYCARBONYL) -ETHYL SQUARE CLAMP ON -9-BROM-1,2,3,4,6,7,12,12B -OCTAHYDROINDOLO SQUARE CLAMP ON 2,3 -A SQUARE CLAMP TO CHINOLIZIN DERIVATIVES, METHOD FOR PRODUCING THE SAME OR. OF 10-BROMVINCAMINE AND 10-BROM-14-EPIVINECAMINE, FIRST-CONTAINING MEDICINAL PRODUCTS AND 1-AETHYL-1 CORNER CLAMP ON 2'- (ACETOXY) -2 '- (METHOXYCARBONYL) -AETHYL-CORNER CLAMP TO , 2,3,4,6,7- HEXAHYDRO-12H-INDOLO ANGLE CLAMP ON 2,3-A ANGLE CLAMP ON CHINOLIZIN-5-IUMPERCHLORATE AND 1-AETHYL-1 SQUARE CLAMP ON 2 '- (HYDROXY) -2 '- (METHOXYCARBONYL) - AETHYL SQUARE CLAMP TO -9-BROM-1,2,3,4, 6,7-HEXAHYDRO-12H-INDOLO SQUARE CLAMP TO 2,3-A SQUARE CLAMP TO CHINOLIZIN 5-IUMPERCHLORATE | |
DE69909960T2 (en) | Cyclopropyl esters of alfa tocopherol, vitamin E derivatives and process for their preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080723 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
17Q | First examination report despatched |
Effective date: 20101118 |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20150701 |